Tin tức & Cập nhật

Treatment with semaglutide and dulaglutide results in a significantly lower risk of adverse cognitive decline in patients with heart failure (HF), as shown by the results of a retrospective cohort study using real-world data.

Treatment with romosozumab for 12 months, followed by 24 months of alendronate, results in significant improvements in lumbar spine areal bone mineral density (BMD) and tissue thickness-adjusted trabecular bone score (TBS) algorithm (TBSTT) compared with alendronate alone among postmenopausal women with osteoporosis and type 2 diabetes (T2D), reports a study.